Paper Details

  1. Home
  2. Paper Details

[Effectiveness of the radioactive strontium (89Sr) chloride agent, SMS.2P for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial].

Author: EndoK, FukudaH, FurudateM, HamamotoK, HisadaK, IchiyaY, IshiiK, KasagiK, KawakamiK, KimuraY, KoizumiK, KonishiJ, KuboA, KusakabeK, MasudaK, NakagawaT, NakajoM, ShishidoF, SuzukiK, TorizukaK, YokoyamaK, YuiN

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

89Sr therapy was effective in alleviating pain in 70% of patients with painful bone metastases and improved their quality of life.
Paper Details　
Original Abstract of the Article :
The phase III clinical trial of strontium-89 chloride agent (SMS.2P) was performed in 90 patients with painful bone metastases secondary to prostate (53), breast (18) and other types of cancer (19). Some patients experienced a transient increase in pain or nausea and vomiting. However both symptoms ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9023442

データ提供：米国国立医学図書館（NLM）

Effectiveness of the Radioactive Strontium (89Sr) Chloride Agent, SMS.2P for Pain Palliation in Patients With Metastatic Bone Tumor in Phase III Multicenter Clinical Trial

The management of [pain associated with metastatic bone tumors] presents a significant challenge for patients. This Phase III clinical trial evaluated the effectiveness of [strontium-89 chloride agent (SMS.2P)] for [pain palliation] in patients with [metastatic bone tumors]. The study found that [SMS.2P significantly improved pain] in [58%] of patients, with [some alleviation] observed in [12%] of participants. This highlights the potential of [SMS.2P] as a valuable treatment option for managing pain in this patient population.

The Effectiveness of SMS.2P for Pain Palliation

The clinical trial demonstrated that [SMS.2P] is effective in [reducing pain] associated with [metastatic bone tumors] for a significant proportion of patients. The study found that [pain relief was observed within days to one week] following treatment, with [lasting effects observed for several months] in some patients. This suggests that [SMS.2P] can provide meaningful relief from pain and improve the quality of life for these individuals.

Finding Relief from Bone Tumor Pain

For patients experiencing the debilitating pain of [metastatic bone tumors], this study offers hope for a [potentially effective treatment option]. The [pain relief] provided by [SMS.2P] could [significantly improve quality of life] for patients. It's essential to [discuss treatment options] with a healthcare professional to determine the best course of action.

Dr.Camel's Conclusion

Pain can be a formidable adversary, but with the right tools, we can find relief. This clinical trial demonstrates the effectiveness of [SMS.2P] in managing pain associated with [metastatic bone tumors], providing a beacon of hope for patients seeking relief from this challenging condition. The study's results encourage us to explore further treatment options and continue our quest for better pain management strategies.

Date :
  1. Date Completed 1997-02-25
  2. Date Revised 2017-02-20
Further Info :

Pubmed ID

9023442

DOI: Digital Object Identifier

9023442

Related Literature

Article Analysis
・Side Effects of strontium-89 chloride
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.